Ada Health
Ada is a clinician-optimized AI symptom assessment tool that helps users understand their health while providing patient triage and touch solutions to enterprise partners.

Recursion uses an AI-native drug discovery platform to decode cellular biology and develop new medicines for cancers and rare diseases.
Recursion is an AI drug discovery company that uses a platform called Recursion OS to decode cellular biology and develop new medicines for cancers and rare diseases. Founded more than a decade ago, the company aims to reduce the 90% failure rate of traditional drug discovery by training artificial intelligence on images of cells to understand the cellular disruptions that drive disease.
At the core of Recursion's approach is the Recursion OS, a drug discovery and development platform that integrates wet-lab automation and machine learning. The system runs up to 2 million weekly experiments, generating a proprietary dataset of over 50 petabytes. This dataset connects biology, generative de novo chemistry, and translational clinical tools, creating a continuous learning loop that systematically de-risks drug discovery. The platform is driven by bilingual teams of scientists and technologists who operate automated labs as an AI-native data factory.
Recursion's pipeline includes potential first-in-class and best-in-class treatments for conditions with high unmet need, such as aggressive cancers and rare diseases. The company has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. One example is REC-3565, a selective MALT1 inhibitor for relapsed or refractory B-cell lymphomas, which has entered Phase 1 clinical testing.
Recursion collaborates with pharmaceutical and technology leaders through strategic partnerships. These alliances accelerate the discovery of new medicines and expand the potential impact on patients. By combining computational titans and next-generation data partnerships, Recursion enhances its capabilities in generative AI for pharma, positioning itself among the top AI drug discovery companies in the industry.
The company leverages patient data to inform its AI drug discovery efforts. By analyzing cellular images and other biological data, Recursion's platform identifies novel insights that guide precision design of potential medicines. This data-driven approach aims to bring better medicines to patients faster, addressing the vast unknown biological space that drives disease.
Recursion's clinical progress includes advancing its pipeline into human trials. The first patient has been dosed in a Phase 1 study of REC-3565, marking a step forward in developing treatments for B-cell lymphomas. The company's work has attracted attention in the broader race to bring AI-discovered drugs to market, as highlighted by media coverage of the multibillion-dollar efforts in this field.
Recursion was founded on the idea that images of cells could train artificial intelligence to understand disease biology. The mission is to decode biology to radically improve lives. By combining physical automation and machine learning models, Recursion aims to systematically de-risk drug discovery and deliver better medicines through novel insights and precision design.
Subscription pricing is not listed.
Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →
Ada is a clinician-optimized AI symptom assessment tool that helps users understand their health while providing patient triage and touch solutions to enterprise partners.
Nabla is a clinical AI layer that captures patient-clinician conversations and generates structured notes, dictation, and coding suggestions inside Epic and major EHRs.
Wysa is an AI-powered mental health support platform that offers safe, clinically backed care for individuals, teams, and health systems. It provides self-help, guided referral, and between-session support through an always-available, anonymous chat interface.
Iambic Therapeutics is a biotech company that uses AI to design differentiated drug candidates, with a clinical pipeline targeting HER2, KIF18A, and CDK2/4.